Kazakhstan, Hong Kong Can Build Biotech Unicorns Through Talent-Capital Link
SCMP · 1 SOURCESabout 4 hours ago2 MIN
Summary
Kazakhstan and Hong Kong could partner to build biotech unicorns by combining the Central Asian country's strong tech workforce with Hong Kong's global financial network. A top academic from Kazakhstan's Nazarbayev University said the two regions could create a substantial biotech ecosystem by connecting entrepreneurs with capital, ideas and government support. The remarks were made at the South China Morning Post's inaugural China Conference: Central Asia 2026 in Astana on Monday.
Key Points
- Huck-Hui Ng, dean of medicine at Nazarbayev University, said linking Kazakhstan's tech talent with Hong Kong's financial infrastructure could produce biotech unicorns valued at US$1 billion or more .
- Kazakhstan's drug regulator became the first in Central Asia to receive World Health Organization certification for meeting global standards in April 2026, supporting the nation's push to become a regional healthcare hub .
- Kazakhstan already has one tech unicorn, Higgsfield AI, a video generation tool developer founded in 2023 and valued at US$1.3 billion as of February 2026 .
- Fariza Zhorabek, R&D lead at Allegrow Biotech (a spin-out from a Hong Kong university), said Hong Kong offers lessons for Kazakhstan including university-level support and research funding .
- Kazakhstan is attracting overseas pharmaceutical manufacturing investments, including from Chinese companies, and is deploying AI for nationwide clinical diagnostics .
Why It Matters
For Hong Kong, this partnership represents an opportunity to expand its financial services into Central Asia's emerging biotech sector while strengthening its role as a bridge between mainland China and new growth markets. The collaboration could attract Kazakhstani entrepreneurs and investment flows to Hong Kong's exchanges and innovation platforms, diversification beyond traditional markets.
For Hong Kong, this partnership represents an opportunity to expand its financial services into Central Asia's emerging biotech sector while strengthening its role as a bridge between mainland China and new growth markets. The collaboration could attract Kazakhstani entrepreneurs and investment flows to Hong Kong's exchanges and innovation platforms, diversification beyond traditional markets.